Form 4: BioXcel Therapeutics CEO Vimal Mehta Reports Stock Transactions

BioXcel Therapeutics CEO Vimal Mehta reports the acquisition and disposal of common stock and restricted stock units, including sales under a pre-arranged 10b5-1 trading plan.

Summary

• Vimal Mehta, CEO and President of BioXcel Therapeutics, reported transactions involving the company's common stock and restricted stock units (RSUs).
• On September 14, 2024, Mehta acquired 2,609 shares of common stock through the vesting of RSUs.
• On September 15, 2024, Mehta acquired 3,500 shares of common stock through the vesting of RSUs.
• On September 16, 2024, Mehta sold 832 shares at $0.6885 and 1,150 shares at $0.6905.
• Following these transactions, Mehta directly owns 51,666 shares of common stock.
• Mehta also indirectly owns 2,000 shares through a spouse and may be deemed the beneficial owner of 7,685,501 shares held by BioXcel LLC.
• The sales on September 16, 2024, were executed under a Rule 10b5-1 trading plan adopted on December 14, 2023.
• Mehta disclaims beneficial ownership of the shares held by BioXcel LLC except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: This is a neutral regulatory filing, reflecting standard insider trading activity. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Management Comments

• The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
• This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It's common for executives to have 10b5-1 trading plans to avoid accusations of insider trading.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The information provided is consistent with the level of detail expected in such filings.
• The use of a 10b5-1 trading plan is a common and accepted method for insiders to manage their stock transactions.

Stakeholder Impact

• The reported transactions may have a minor impact on shareholders, potentially influencing short-term stock price fluctuations.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

BioXcel Therapeutics, BTAI, Vimal Mehta, Form 4, Stock Transactions, Restricted Stock Units, 10b5-1 Trading Plan, Beneficial Ownership